Endologix announced that it has acquired the Pounce Thrombectomy System from Surmodics in a transaction that closed on May 18, 2026. The acquisition expands Endologix’s vascular intervention portfolio with a fully mechanical thrombectomy platform designed for the non-surgical removal of thrombi and emboli from peripheral arteries.
The FDA-cleared Pounce System is built around proprietary dual-basket technology and a nitinol collection funnel. The system is designed to support procedural simplicity, versatility, and efficiency without relying on capital equipment, thrombolytics, or aspiration. The platform includes several commercially available configurations, including Pounce LP, Pounce, and Pounce XL, which are intended to support treatment across a range of peripheral arterial vessel sizes, including smaller and more distal vessels.
Endologix said the Pounce Thrombectomy System will continue to be marketed under its existing FDA clearance during a transition period following the acquisition.
The acquisition expands Endologix’s commercial offering for vascular interventionalists already using the company’s DETOUR, ALTO and AFX2 platforms. By adding a mechanical thrombectomy option, Endologix said it can support a broader continuum of care for patients with peripheral vascular disease. As part of the transaction, a core group of Surmodics employees supporting the Pounce platform will join Endologix.
Endologix is a California-based medical device company focused on therapies for the interventional treatment of vascular disease. Its commercial portfolio includes the AFX®2 Endovascular AAA System, ALTO® Abdominal Stent Graft System, and DETOUR System. The company is wholly owned by Deerfield Management.
KEY QUOTES:
“The Pounce Thrombectomy System is a strong strategic and clinical fit for Endologix. It serves the same physicians and patients we already work with every day and brings a clinically differentiated mechanical approach that complements our vascular intervention portfolio. We are excited to welcome members of the Pounce team as part of our intentional investment in innovation that helps vascular specialists deliver better care.”
John Liddicoat, M.D., President and Chief Executive Officer, Endologix
“I have used both Pounce and Endologix technologies in my practice, and bringing these solutions together under one organization makes a great deal of clinical sense. The Pounce fully mechanical thrombectomy system offers a grab-and-go solution that does not rely on thrombolytics or aspiration and complements Endologix’s portfolio of vascular technologies for the treatment of peripheral arterial disease. Together, these technologies provide physicians with additional flexibility when addressing thrombi and emboli in the peripheral arterial vasculature.”
Venkatesh Ramaiah, M.D., FACS, Chief of Vascular and Endovascular Surgery, Pulse Cardiovascular Institute
